Bullous pemphigoid during ustekinumab therapy  by Le Guern, Aurore et al.
CASE REPORTBullous pemphigoid during ustekinumab therapy
Aurore Le Guern, MD,a Salim Alkeraye, MD,c Annie Vermersch-Langlin, MD,a
Patrick Coupe, MD,b and Marlene Vonarx, MDa
Valenciennes and Lille, FranceFrom
en
Ho
Fund
Confl
Corre
De
59Key words: bullous perphigoid; tumor necrosis factor; ustekinumab therapy.Abbreviations used:
BP: Bullous pemphigoid
TNF-a: tumor necrosis factor-alfaINTRODUCTION
Ustekinumab, a monoclonal antibody that blocks
interleukin-12 and interleukin-23, is a biological
therapy used to treat moderate-to-severe psoriasis.
Bullous pemphigoid (BP) induced by antietumor
necrosis factor-alfa (TNF-a) agents has been
described in the literature.1-3 No cases have been
reported with ustekinumab. We report a case of BP
occurring in a patient treated for 9 months with
ustekinumab for severe psoriasis.
CASE REPORT
A 62-year-old man with a greater-than 20-year
history of chronic plaque psoriasis presented with
new-onset pruritic bullae. He had a history of hyper-
tension and was treated with metformin for type 2
diabetes. There was no personal or family history of
autoimmune disease. After unsuccessful systemic
therapies (acitretin, methotrexate) and antieTNF-a
agents (etanercept, adalimumab), ustekinumab was
introduced in September 2012. The patient received 5
subcutaneous injections: 45 mg at weeks 0, 4, 16 and
90 mg at weeks 28 and 40 (the dose was increased
because the patient gained weight). The patient
noticed the eruption of pruritic bullae in June 2013,
3 days after the fifth injection. Physical examination
found tense bullae on erythematous patches and
urticarial plaques predominantly on the upper
thighs, lower neck, and upper trunk (Figs 1 and 2).
There were no mucosal lesions and Nikolsky’s sign
was absent. Psoriatic plaques on the trunk and lower
limbs were present. Histologic examination found a
dermo-epidermal detachment with eosinophilic
infiltration. The direct immunofluorescence high-
lighted deposits of IgG and C3 along the basal
membrane (Fig 3). Cutaneous immunofluorescence
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Cessation of ustekinumab and the use of topical
corticosteroids resulted in complete regression of the
urticarial plaques and bullae within 3 weeks. The
patient’s psoriasis flared in December 2013, and he
was started on infliximab with good results. No
relapse of bullous disease was observed 18 months
after withdrawal of ustekinumab and 14 months after
stopping topical steroids.
DISCUSSION
Many drugs may induce BP, including antibiotics
(penicillin, fluoroquinolone, chloroquine, rifam-
picin), diuretics (furosemide, spironolactone),
and angiotensin-converting enzyme inhibitors.4
Although an association between frequency of BP
and psoriasis may exist,5 several cases of bullous
pemphigoidwere attributed to antieTNF-a agents.1-3
To our knowledge, no case of BP has been described
during ustekinumab use, but its mechanism of action,
leading to down-regulation of TNF-a, makes it
possibly accountable. Ustekinumab blocks the dif-
ferentiation and clonal expression of Th1 and Th17
effector cells. It results in a reduced production of
pro-inflammatory cytokines, including TNF-a
agents.6 Although the mechanism is not yet
understood, the modification of the immune
response could cause the onset of BP. Other effects
of inflammatory or immune skin disorders have
also been reported with ustekinumab use, including
cases of alopecia areata,7 linear IgA dermatosis,8JAAD Case Reports 2015;1:359-60.
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Fig 1. Tense bullae of the upper trunk.
Fig 2. Tense bullae of the upper trunk.
Fig 3. Direct immunofluorescence: linear highlight in the
basal membrane zone (deposits of IgG and C3 along the
basal membrane).
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of this cytokine imbalance. In our case, several
factors argue in favor of an iatrogenic origin: the
relatively early age of onset, acute and limited nature
of the lesions, their rapid regression after stopping
ustekinumab, and no recurrence after 18 months.
Metformin’s causation was less probable since the
patient had been on this medication for many years
and because no cases of BP with Metformin’s use
have been reported. Additionally, infliximab may
have had an impact on this patient’s BP, as this
treatment was introduced a few months after cessa-
tion of ustekinumab to treat psoriasis. Some cases of
BP have been treated successfully with antieTNF-a
agents.10-12 BP has also been treated successfully with
ustekinumab in one report, which makes the whole
question of causation and effect more difficult for the
biologics.13 It suggests the involvement of other
cytokinic pathways in our case, independent
from TNF-a agents, in the occurrence of iatrogenic
pemphigoid. To our knowledge, we report the
first case of BP during ustekinumab therapy.
With the increasing use of newly marketed
biologics, new cutaneous side effects may occur in
the future.REFERENCES
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